Eagle Pharmaceuticals, Inc. Reports Third Quarter 2015 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- Tesla acquires AI hardware company for up to $2 billion in stock
- Bel Fuse acquires dataMate ethernet business for $16 million
- Fed: Nine Of 18 FOMC Participants Pencil In 2026 Rate Hike
Eagle Pharmaceuticals (EGRX) Reports Tough 3Q Results; Piper Jaffray Cuts Price target to $97
November 12, 2015 9:29 AM ESTPiper Jaffray reiterates an Overweight rating on Eagle Pharmaceuticals (NASDAQ: EGRX), and cut the price target to $97.00 (from $120.00), following the company's 3Q earnings report. Eagle reported EPS of ($0.65) on revenues of $6M, missing consensus on both. Analyst David Amsellem continues to believe there is optionality associated with Ryanodex in exertional heat stroke (EHS),... More
Eagle Pharmaceuticals (EGRX) Misses Q3 EPS by 9c
November 11, 2015 7:04 AM ESTEagle Pharmaceuticals (NASDAQ: EGRX) reported Q3 EPS of ($0.65), $0.09 worse than the analyst estimate of ($0.56). Revenue for the quarter came in at $3.3 million versus the consensus estimate of $5.07 million.
"Eagle has accomplished a great deal already this year, and we remain focused on achieving our goals in the particularly exciting and important final weeks ahead, said Scott Tarriff, President and Chief... More
